Search research articles
Contact Us
Filters
Showing results (61-70 of 91) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2017
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)
Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Cancer Research
|
July 4, 2012
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis
Austin M Dulak, Steven E Schumacher, Jasper van Lieshout, et al.
The Lancet. Oncology
|
February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
Victoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab
Ryan J Park, Milan Parikh, Leon Pappas, et al.
Nature Communications
|
August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Harshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Cancer
|
March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial
James M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JCO Precision Oncology
|
June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer
Harshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Journal for Immunotherapy of Cancer
|
October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
Leonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 91) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2017
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)
Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Cancer Research
|
July 4, 2012
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis
Austin M Dulak, Steven E Schumacher, Jasper van Lieshout, et al.
The Lancet. Oncology
|
February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans
Victoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab
Ryan J Park, Milan Parikh, Leon Pappas, et al.
Nature Communications
|
August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Harshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Cancer
|
March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial
James M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JCO Precision Oncology
|
June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer
Harshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Journal for Immunotherapy of Cancer
|
October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
Leonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
Page
of 10